NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation

/EIN News/ -- TORONTO and HAIFA, Israel, Feb. 14, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is excited to announce that it will be presenting at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting (“ISCT 2025”), a major global cell and gene therapy translation conference, taking place from May 7-10, 2025 in New Orleans, Louisiana, United States.

As part of the Company’s growth and awareness strategy for its expansion into the United States, NurExone will be highlighting its innovative ExoPTEN therapy in a presentation during ISCT 2025 titled: “ExoPTEN: Allogeneic Exosome Therapy for Spinal Cord Injury with Strong Therapeutic Potential and Clinical Promise.” The presentation will cover the Company’s robust preclinical data, demonstrating that a minimally invasive ExoPTEN treatment cycle significantly improved motor and sensory functions and structural recovery in small animal models of spinal cord injury.

“We are honored to present this cutting-edge research to leading experts in the field and further establish our position as a pioneer in exosome-based regenerative therapies,” said Dr. Tali Kizhner, Director of Research and Development at NurExone. “Participating in high-profile U.S. conferences such as ISCT 2025 is central to our strategy of increasing NurExone’s visibility within the North American biotech and investor communities.”

The Company’s presence at ISCT 2025 underscores its commitment to advancing its innovative therapies globally. Recently, NurExone launched its U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), which will focus on the production and supply of high-quality, fully characterized good manufacturing practice (“GMP”) exosomes for research and therapeutic use. The exosomes produced will be used for NurExone’s product development as well as for supply to third parties, further expanding the Company’s footprint in the U.S. market. See the Company’s press release dated February 5, 2025, for more details on the establishment of Exo-Top.

Eran Ovadya, Chief Financial Officer of NurExone stated, “The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S. listing opportunities, presenting at prestigious events is expected to strengthen our strategy and increase shareholder value.”

About NurExone

NurExone Biologic Inc. is a TSX Venture Exchange (“TSXV”), OTCQB and Frankfurt listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, two multi-billion-dollar markets. Regulatory milestones, including Orphan Drug Designation, facilitate the roadmap towards clinical trials in the U.S and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top, a U.S. subsidiary, to anchor its North American activity and growth strategy.

For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.

For more information, please contact:

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Oak Hill Financial Inc.
2 Bloor Street, Suite 2900
Toronto, Ontario M4W 3E2
Investor Relations – Canada
Phone: +1-647-479-5803
Email: info@oakhillfinancial.ca

Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu

Allele Capital Partners
Investor Relations – U.S.
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com

FORWARD-LOOKING STATEMENTS

This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the Company’s proposed attendance and presentation at ISCT 2025; the Company’s presence at ISCT 2025 helping it expand its U.S. presence, strengthen its strategy, increase shareholder value, further establish its position as a leader in exosome-based regenerative medicine, and increase the Company’s visibility within the North American biotech and investor communities; the Company highlighting its ExoPTEN treatment therapy and the Company’s preclinical data during the presentation; the Company establishing Exo-Top to support the future development of GMP exosome production and the intended benefits of its establishment on the Company and its business; Exosomes produced by Exo-Top will be used for product development, supplied to third parties, as well as further expanding the Company’s footprint in the US ; broader adoption of exosomes in the field and cell therapy applications; the Company’s future plans and expectations; growing clinical demand for innovative treatments in spinal cord, optic nerve, and other therapeutic areas; NurExone advancing its development pipeline; NurExone is focused on developing regenerative exosome-based therapies for central nervous system injuries; and the NurExone platform technology offering solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.

These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company will attend and present at ISCT 2025; the Company’s presence at ISCT 2025 will help it expand its U.S. presence, strengthen its strategy, increase shareholder value, further establish its position as a leader in exosome-based regenerative medicine, and increase the Company’s visibility within the North American biotech and investor communities; the Company will highlight its ExoPTEN treatment therapy and the Company’s preclinical data during the presentation; the Company establishing Exo-Top will support the future development of GMP exosome production and the intended benefits of its establishment on the Company and its business; Exosomes produced by Exo-Top will be used for product development, supplied to third parties, as well as will expand the Company’s footprint in the U.S.; there will be broader adoption of exosomes in the field and cell therapy applications; the Company’s future plans and expectations; there will be growing clinical demand for innovative treatments in spinal cord, optic nerve, and other therapeutic areas; NurExone will advance its development pipelines; NurExone will be focused on developing regenerative exosome-based therapies for central nervous system injuries; and the NurExone platform technology will offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company’s early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel, and on the Company’s strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company’s intellectual property and technology won’t have the intended impact on the Company and/or its business; the Company’s inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the inability of the Company to realize on the benefits of exosomes; the inability of the Company to produce and/or supply exosomes for a wide range of applications; the inability of the Company’s products to be used for patient treatment; there not being broader adoption in the field and/or cell therapy applications; the inability of the Company to fulfill its intended future plans and expectations; there not being growing clinical demand for innovative treatments in spinal cord, optic nerve, and/or other therapeutic areas; the inability of the Company to collaborate with pharma companies; the Company’s inability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company’s inability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine and/or cell therapy applications; the Company’s inability to expand into further studies; Exo-Top not have the intended benefits on the Company and/or its business; the establishment of Exo-Top not supporting the future development of GMP exosome production; the Company’s inability to attend and present at ISCT 2025; the Company’s presence at ISCT 2025 will not help it expand its U.S. presence, strengthen its strategy, increase shareholder value, further establish its position as a leader in exosome-based regenerative medicine, and increase the Company’s visibility within the North American biotech and investor communities; the Company not highlighting its ExoPTEN treatment therapy and the Company’s preclinical data during the presentation; Exosomes produced by Exo-Top will not be used for product development, supplied to third parties, or help expand the Company’s footprint in the U.S.; there not being a broader adoption of exosomes in the field and cell therapy applications; the Company’s products will not be used for patient treatment; there will not be growing clinical demand for innovative treatments in spinal cord, optic nerve and/or other therapeutic areas; NurExone being unable to advance its development pipeline; NurExone will not have the ability to focus on developing regenerative exosome-based therapies for central nervous system injuries the NurExone platform technology not offering solutions to drug companies interested in minimally invasive targeted drug delivery for other indications; and the risks discussed under the heading “Risk Factors” on pages 44 to 51 of the Company’s annual information form dated August 27, 2024, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.